BHC
Bausch Health Companies Inc
Bausch Health Companies Inc historical holders
total: 7
ValueAct Holdings Bausch Health Companies Inc transactions over time
- Total transactions:
- 7
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 4
- Held since:
- 2018 Q3
- Held for:
- 16 quarters
- Latest activity:
- 2022 Q3
Jeffrey Ubben has been an institutional investor in Bausch Health Companies Inc (BHC) since 2018 Q3. According to 2026 Q1 report, Jeffrey Ubben doesn't hold any shares. The fund/company first acquired BHC in 2018 Q3, initially purchasing about 18.03M shares. Since the initial investment, ValueAct Holdings has made 6 more transactions in this position.
When did Jeffrey Ubben exit their BHC position?
Jeffrey Ubben no longer holds Bausch Health Companies Inc (BHC). They sold off their entire position in 2022 Q3, closing out an investment that began in 2018 Q3.
When did Jeffrey Ubben first invest in BHC?
Jeffrey Ubben first invested in Bausch Health Companies Inc (BHC) in 2018 Q3 at the reported quarter-end price of $25.67 per share, acquiring 18,033,149 shares in their initial purchase.
What is Jeffrey Ubben's average cost basis for BHC?
Based on historical transaction data, Jeffrey Ubben's estimated cost basis for Bausch Health Companies Inc (BHC) is approximately $25.67 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $25.67
- Weighted AVG sell price:
- $11.89
BHC transactions history by ValueAct Holdings
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q3
|
0.00%
|
0
|
$8.36
|
|
-100% (-14,341,265)
|
-1.91%
|
|
2022 Q2
|
1.91%
|
14,341,265
|
$8.36
|
$119,893,000
|
-0.62% (-89,636)
|
-0.01%
|
|
2022 Q1
|
4.54%
|
14,430,901
|
$22.85
|
$329,746,000
|
-7.59% (-1,185,860)
|
-0.31%
|
|
2021 Q4
|
4.86%
|
15,616,761
|
$27.61
|
$431,179,000
|
-12.96% (-2,324,842)
|
-0.74%
|
|
2020 Q4
|
4.33%
|
$20.80
|
+0.06% (+10,009)
|
|||
|
2019 Q2
|
4.72%
|
$25.22
|
-0.56% (-101,555)
|
|||
|
2018 Q3
|
4.55%
|
$25.67
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.